Meta Analysis of Efficacy and Safety of Ropinirole in the Treatment of Parkinson’s Disease
- VernacularTitle: 罗匹尼罗治疗帕金森病有效性和安全性Meta分析
- Author:
Mingyue ZHAI
1
;
Shuo ZHANG
1
;
Ligang JIANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Ropinirole; Parkinson’s disease; Observational study; Meta-analysis
- From: Journal of Apoplexy and Nervous Diseases 2020;37(3):232-236
- CountryChina
- Language:Chinese
- Abstract: Objective To investigate the efficacy and safety of ropinirole in treating Parkinson’s Disease （PD） by meta-analysis of clinical randomized controlled studies. Methods The American national Library of medicine （Pubmed），Cochrane Library （Cochrane Library），Dutch medical literature database （Embase），CNKI （CNKI），wanfang knowledge service platform，and wiper journal network were searched by computer to search the relevant studies on the efficacy and safety of ropinello in the treatment of Parkinson’s disease. The scores of the unified Parkinson’s disease assessment scale part Ⅱ （UPDRS Ⅱ），part Ⅲ （UPDRS Ⅲ） and the incidence of adverse events in each group were extracted. Cochrane risk bias assessment tool was used to evaluate the quality of the included literature，and RevMan5.3 software was used for Meta analysis. Results A total of 732 articles were found through computer database retrieval，and 12 RCT studies on the efficacy and safety of PD treatment with ropinero were finally included，including 1855 patients in the experimental group and 1486 patients in the control group. Results of meta-analysis showed that，compared with placebo group，the scores of UPDRS Ⅱ（MD -2.23，95%CI -2.82~-1.64，P<0.00001） and UPDRS Ⅲ（MD -4.93，95%CI -5.25~-4.61，P<0.00001） in the treatment of Parkinson’s disease in the ropinelo group were more significantly reduced in terms of drug efficacy. In terms of the incidence of adverse reactions，the incidence of dyspraxia （RR 3.67，95%CI 2.57~5.24，P<0.00001），dizziness （RR 1.85，95%CI 1.50~2.28，P<0.00001），nausea （RR 2.17，95%CI 1.81~2.59，P<0.00001），vomiting （RR 2.73，95%CI 1.47~5.09，P=0.001） and sleepiness （RR 2.19，95%CI 1.39~3.44，Both P=0.0007） were higher than those in the placebo group，with statistically significant differences. The incidence rates of headache （RR 1.14，95%CI 0.79~1.65，P=0.49），insomnia （RR 1.06，95%CI 0.72~1.55，P=0.17），postural hypotension （RR 1.35，95%CI 0.81~2.22，P=0.25） and constipation （RR 1.03，95%CI 0.71~1.50，P=0.87） were all lower than those of the placebo group，with no statistically significant difference. Conclusion In this study，the method of meta-analysis showed that the improvement rate of daily living ability and motor function score of PD patients treated with ropinelol was significantly higher than that of patients receiving placebo. Ropinelol was well tolerated and safe，and most adverse reactions were related to peripheral dopaminergic activities.
- Full text:2024080211580715892罗匹尼罗治疗帕金森病有效性和安全性Meta分析.pdf
